VABMT Banner


The Acute Lymphoblastic Leukaemia (ALL) Landscape in 2020
Tuesday, 22 Sep 2020
20:00 (UTC+8)



Acute lymphoblastic leukaemia (ALL) in children is a success story of medical history achieving nearly 90% cure rate with appropriate therapy. Advancement in investigation facilities including cytogenetics, genomic analysis and minimal residual estimation has helped in tailoring therapy according to risk groups to achieve cure at least cost. Despite of this success a small percentage of children with high risk features and poor response to therapy need new treatment modalities including immunotherapy and stem cell transplant for improvement in outcome. Relapse after initial remission and refractoriness to current chemotherapy agents still remains a challenge for a small group of children where new therapies are necessary to achieve cure. 

Professor Hiroto Inaba discusses the optimal use of Immunotherapy agents in high risk ALL and how we can reduce the relapse risk in such children. Professor Vaskar Saha discusses the strategies of treating relapsed refractory ALL highlighting the lessons learnt from R3 and IntReALL trials. He also discusses how these strategies can be adapted in developing world to improve outcome in children who currently have poor prognosis without very advanced treatment facilities. 






Prof Hiroto Inaba

Member, Leukemia/Lymphoma Division, Department of Oncology
St. Jude Children’s Research Hospital
Memphis, Tennessee, USA

Professor Inaba completed his MD, PhD at Mie University School of Medicine in Japan. Currently, he is a Member in the Department of Oncology at St. Jude, where he is engaged in the care of and research on patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia, and non-Hodgkin lymphoma. In 2011 he received an outstanding physician award for his dedicated patient care at St. Jude, and in 2013 he received the Joseph V. Simone, MD, Golden Apple Award for his excellent teaching of trainees. 

He has published more than 100 articles and has several research focuses. One of his research goals is to develop a new treatment regimen for patients with newly diagnosed ALL that will further increase the survival rate while reducing the adverse effects of treatment. He is the principal investigator of the St. Jude frontline ALL protocol, Total 17, and he is engaged in the blinatumomab humanitarian access program (a donation program to supply blinatumomab to regions where there is no access to the drug) in collaboration with Amgen.


Prof Vaskar Saha

Professor of Paediatric Oncology, University of Manchester
Head, Paediatric Haematology and Oncology, Tata Medical Center, Kolkata
Director Tata Translational Cancer Research Centre, Kolkata
DBT-Wellcome Margdarshi Fellow
United Kingdom

Professor Saha is clinician scientist in the field of childhood acute lymphoblastic leukaemia. He is past chair of the UK ALL subgroup, I-BFM resistant disease group and INPOG ALL subcommittee. He investigates the variations in responses to therapy in children with acute lymphoblastic leukaemia recruited to multicentre clinical trials.


Dr Rajat Bhattacharyya

Senior Consultant, Paediatric Haematology Oncology BMT
KK Women’s and Children’s Hospital

Dr Bhattacharyya did his undergraduate medical training (MBBS)and post graduate paediatric training (MD) from Medical College Kolkata, India. Then he pursued his further paediatric and haematology training in UK and completed Specialist Registrar training (CCT in Haematology UK). He also did 1 year fellowship in paediatric haematology oncology in Vancouver Children’s Hospital, Canada. Currently he is working as a senior consultant in KK Hospital, Singapore since March 2013. His special interest is malignant haematological conditions, stem cell transplantation and cellular therapy.  


This educational material is intended to provide information on research activities and may refer to products not approved for use in Singapore and/or unapproved uses of products approved in Singapore. The views expressed in this presentation are those of the presenter. Amgen Singapore does not endorse the promotion of unapproved products or indications.

This webinar is sponsored with an educational grant from Amgen. Participants are invited to connect with AMGEN via: